BOSTON, March 3 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced
today the appointment of John P. Dunphy to the position of Vice President and
Chief Financial Officer. As CFO, Mr. Dunphy will have overall responsibility
for the Company's finance, accounting and investor relations functions,
building on more than 25 years of capital markets experience on Wall Street
working with private and public companies. Executive management team member
Beverly A. Armstrong will continue to direct internal operations as Vice
President of Administration and has been appointed to the newly created
positions of General Counsel and Chief Compliance Officer, where she will
focus on governance, risk management and Sarbanes-Oxley compliance.
Mr. Dunphy's expertise in equity and debt syndicate efforts includes a 13-
year tenure as a Managing Director of SG Cowen's Equity Capital Markets Group
(1989 to 2002). At Cowen, Mr. Dunphy focused on structuring, marketing and
syndicating the firm's healthcare transactions. In 2002, he assumed the role
of Chief Financial Officer at Idenix Pharmaceuticals, where, among other
things, he provided financial leadership during the Idenix team's negotiation
of a significant collaboration with Novartis.
Prior to joining SG Cowen, Mr. Dunphy served as a Senior Vice President
and Syndicate Manager at Butcher & Singer, where he was also a member of the
company's Board of Directors. Mr. Dunphy was also General Partner and Head of
Syndicate at McDonald & Company Securities. He is active in several
securities industry professional associations and is a member of the Board of
Governors of the Bond Club of New York and was a member of The Syndicate
Committee of the Securities Industry Association. Mr. Dunphy received his
M.B.A. degree from Ohio State University and his B.A. degree in Economics from
"As Paratek prepares to enter the next stage of its life, Jack's depth of
financial expertise and public markets experience, along with his track record
with healthcare and biotech companies, will be invaluable to Paratek,"
commented Paratek Pharmaceuticals' Chief Executive Officer, Thomas J. Bigger.
"Jack has directly participated in many of the success stories in this
industry, particularly in his role as a managing director at SG Cowen's Equity
Capital Markets Group, and we believe his perspective will be crucial in
Paratek's continued success as well."
Beverly Armstrong commented, "Jack is a Wall Street veteran with unmatched
capabilities and expertise. We are extremely pleased that the strength and
depth of Paratek's scientific platforms and product pipeline have attracted
him to our management team as we near an inflection point in Paratek's
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by interfering with Multiple Adaptational Response (MAR)
mechanisms in bacteria. Out of these efforts, Paratek has discovered a new
class of antibiotics, the aminomethylcyclines that target the need for new and
potent antibacterials to overcome the problem of rapidly growing bacterial
resistance. The Company's lead antibiotic clinical candidate, PTK 0796, the
first product from this class, is being developed for the treatment of serious
Outside the antibacterial therapeutic area, Paratek has also established
an internal effort to exploit its novel families of compounds and their unique
mechanism of action in selected anti-inflammatory and neurodegenerative
conditions. Paratek has an active chemical synthesis effort to produce novel
and diverse small molecules, with the goal of developing non-antibacterial
products with improved activity in serious diseases based upon a growing body
of clinical and basic research supporting this approach.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com/.
SOURCE Paratek Pharmaceuticals, Inc.